Virkelighedsundersøgelse af orale upadacitinib-tabletter for at vurdere uønskede hændelser og ændring i sygdomsaktivitet hos unge og voksne kinesiske deltagere med atopisk dermatitis
En prospektiv, multicenter, post-marketing, observationel undersøgelse for at evaluere sikkerheden og effektiviteten af upadacitinib hos kinesiske unge og voksne patienter med moderat til svær atopisk dermatitis (AD)
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how safe and effective upadacitinib is in treating AD in adolescent and adult Chinese participants.
Upadacitinib is an approved drug for treating AD. Approximately 200 adolescent and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in China.
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed up for approximately 24 months per participant and 30 days after last treatment dose for safety data collection.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
Studieoversigt
Status
Status
Betingelser
Betingelser
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100191
- Peking University Third Hospital /ID# 257722
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350005
- The First Affiliated Hospital Of Fujian Medical University /ID# 257725
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510091
- Dermatology Hospital of Southern Medical University /ID# 261862
-
Shenzhen, Guangdong, Kina, 518033
- The Eighth Affiliated Hospital, Sun Yat-sen universtiy /ID# 257737
-
-
Henan
-
Zhengzhou, Henan, Kina, 450003
- People's Hospital of Henan Province /ID# 257736
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 257724
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110001
- First Affiliated Hospital of China Medical University /ID# 257641
-
-
Shaanxi
-
Xi'an, Shaanxi, Kina, 710004
- Second Affiliated Hospital of Xian Jiaotong University /ID# 257733
-
-
Shandong
-
Jinan, Shandong, Kina, 250022
- Shandong Dermatological Hospital /ID# 257727
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200040
- Huashan Hospital, Fudan University /ID# 256456
-
Shanghai, Shanghai Municipality, Kina, 200065
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 257726
-
Shanghai, Shanghai Municipality, Kina, 200443
- Shanghai Skin Disease Hospital /ID# 257719
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610017
- Chengdu Second Municipal People's Hospital /ID# 257732
-
Chengdu, Sichuan, Kina, 610041
- West China Hospital, Sichuan University /ID# 257720
-
Chengdu, Sichuan, Kina, 610072
- Sichuan Provincial People's Hospital /ID# 263898
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310003
- Hangzhou First People's Hospital /ID# 261867
-
Hangzhou, Zhejiang, Kina, 310009
- The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 257723
-
Ningbo, Zhejiang, Kina, 315010
- Ningbo First Hospital /ID# 263884
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Adolescent and adult Chinese participants with atopic dermatitis (AD) who are prescribed Upadacitinib by their physician according to their local label.
Beskrivelse
Inclusion Criteria:
- Diagnosis of moderate to severe atopic dermatitis (AD) at the time of enrollment.
- Chinese adolescents (≥12 to <18 years of age with body weight of ≥40 kg) or adults (≥18 years of age) at the time of enrollment.
- Participants eligible for initiation of Upadacitinib treatment for AD, including any required screening tests indicated per China Label.
- The decision to prescribe Upadacitinib is made prior to and independently of study participation.
Exclusion Criteria:
- Participants who cannot be treated with Upadacitinib as per China label or by judgement of treating physician.
- Currently participating in any interventional research studies.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
|---|
|
Upadacitinib
Adolescent and adult participants will receive upadacitinib as prescribed by their physician irrespective of the study participation. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants With Incidence of Serious Infections
Tidsramme: Up to approximately 25 months
|
Incidence rate of serious infections in AD participants treated with Upadacitinib will be assessed. |
Up to approximately 25 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: ABBVIE INC., AbbVie
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- P21-702
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .